Image

North America Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Medical Devices

Image

North America Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2030

  • Medical Devices
  • Published Report
  • Dec 2022
  • North America
  • 350 Pages
  • No of Tables: 100
  • No of Figures: 42

North America Lung Cancer Diagnostics Market – Industry Trends and Forecast to 2030

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2023–2030
Diagram Market Size (Base Year) USD 0.00
Diagram Market Size (Forecast Year) USD 0.00
Diagram CAGR %

North America Lung Cancer Diagnostics Market, By Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.

North America Lung Cancer Diagnostics Market

North America Lung Cancer Diagnostics Market Analysis and Insights

The North America lung cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. Increasing lung cancer diagnosis and development research is further projected to boost market growth. However, difficulties in lung cancer screening techniques might hamper the growth of the North America lung cancer diagnostics market in the forecast period.

North America Lung Cancer Diagnostics Market

North America Lung Cancer Diagnostics Market

Increasing healthcare expenditure on cancer diagnosis and treatment is expected to give opportunities to the market to enhance the treatment. However, the high cost of testing and strict regulations and standards for the approval and commercialization of cancer diagnostic products may challenge market growth.

The North America lung cancer diagnostics market is supportive and aims to reduce the progression of the disease. Data Bridge Market Research analyses that the North America lung cancer diagnostics market will grow at a CAGR of 14.6% during the forecast period of 2023 to 2030.

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2020 - 2015)

Quantitative Units

Revenue in USD Million, Pricing in USD

Segments Covered

Product Type (Instruments, Consumables & Accessories), Test Type (Biomarkers Test, Imaging Test, Biopsy, Blood Test, and Others), Cancer Type (Non-Small Cell Lung Cancer, Small Cell Lung Cancer), End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales)

Countries Covered

U.S., Canada, Mexico

Market Players Covered

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others

Market Definition

Cancer begins in the lungs and most often occurs in people who smoke. Two major types of lung cancer are non-small cell lung cancer and small cell lung cancer. Causes of lung cancer include smoking, second-hand smoke, exposure to certain toxins, and family history.

Symptoms include a cough (often with blood), chest pain, wheezing, and weight loss. These symptoms often don't appear until the cancer is advanced. Treatments vary but may include surgery, chemotherapy, radiation therapy, targeted drug therapy, and immunotherapy.

North America Lung Cancer Diagnostics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

  • Increasing early diagnosis of lungs cancer

Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.

The likelihood of successfully treating cancer is considerably increased by early identification. The two elements of early cancer detection are screening and early diagnosis (or downstaging). While screening consists of evaluating healthy individuals to find those who have cancer before any symptoms occur, early diagnosis focuses on identifying symptomatic patients as early as feasible.

  • Detection of early-stage cancers often limited by high false positives and poor sensitivity

The creation of non-invasive tests that can quickly and reliably identify whether and where in the body a person has early-stage cancer is one of the most promising areas of cancer prevention research. And not just one cancer but a variety of cancers. On this front, significant advancements have been made in recent years. Several multi-cancer early detection (MCED) tests are currently under development, and they are designed to screen for multiple cancer types in otherwise healthy individuals simultaneously. However, detecting early-stage cancer is a challenge as it comes with many barriers, such as high false positives or poor sensitivity. Many cases of poor diagnostics sensitivity lead to a patient's life at risk. The high false positives are also one of the causes of cancer advancing to late stages or advanced stages.

Thus, the detection of early-stage cancers is often limited by high false positives, and sometimes poor sensitivity may act as a major restraining factor for the growth of the North America lung cancer diagnostics market.

  • Rise in healthcare expenditure for cancer diagnosis and treatment

Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Whereas the healthcare industry ranks second among all industries when it comes to the amount spent on healthcare. Rising healthcare expenditure can result in better provision of research and development opportunities. It is anticipated to increase the demand for lung cancer diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and sources. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity to grow the market's demand.

  • Lack of skilled and certified professionals

The requirement of skilled and certified professionals is a big restraint for cancer diagnostics. The demand for cancer diagnostic is increased due to increasing cases of cancer disease in the globe, but the fewer number of skilled professionals present in the diagnostic center is hampering the growth of the market.

The instruments, methods, and procedures of cancer diagnosis have been advanced, but there are certain gaps in standardization, equalization, and knowledge. Technicians face technical training gaps related to problems and adapt advanced methods safely to perform procedures efficiently. In cancer diagnostics, skilled professionals are highly needed for method development, validation, operation, and troubleshooting activities.

A cancer diagnosis is a dynamic component in today's complex time, providing patients with essential information for diagnosing, preventing, treating, and managing their cancer disease. The requirement for trained staff is a big issue for the North America lung cancer diagnostics market. Due to the lack of skilled and certified professionals, end users cannot install advanced products for a cancer diagnosis; this may challenge the growth of the North America lung cancer diagnostics market.

Post-COVID-19 Impact on North America Lung Cancer Diagnostics Market

The high burden of COVID-19 on healthcare systems around the world has raised concerns among medical oncologists about the impact of COVID-19 on lung cancer diagnosis and treatment. We investigated the impact of COVID-19 on lung cancer diagnosis and treatment before and after the COVID-19 era in this retrospective cohort study. During the pandemic, new lung cancer diagnoses decreased by 34.7% with slightly more advanced stages of the disease, and there was a significant increase in radiosurgery as the first definitive treatment and a decrease in systemic treatment and surgery compared to the pre-COVID-19 era. Compared to pre-COVID-19 times, there was no significant delay in starting chemotherapy and radiation treatment during the pandemic.

During the pandemic, however, we observed a delay in lung cancer surgery. COVID-19 appears to have significantly impacted lung cancer patients' diagnoses and treatment patterns at our lung cancer center. Many oncologists are concerned that the number of newly diagnosed lung cancer patients will rise in the coming year. This research is still ongoing, and more information will be gathered and analyzed to understand better the overall impact of the COVID-19 pandemic on our lung cancer patient population.

Recent Developments

  • In October 2022, Quest Diagnostics announced a new chapter of the partnership with Decode Health. This partnership has aided the business in decreasing the time and expense involved in creating fresh diagnostic tests and finding new medication targets for various cancers and increased the company's North America presence
  • In August 2022, F. Hoffmann-La Roche Ltd. announced the launch of a Digital LightCycler System, a next-generation digital PCR system that helps clinical researchers better understand the nature of a patient's cancer, genetic disease, or infection. This system is designed for laboratories performing highly sensitive and precise DNA and RNA analysis in oncology and infectious diseases

North America Lung Cancer Diagnostics Market Scope

The North America lung cancer diagnostics market is categorized into five notable segments based on product type, test type, cancer type, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.

Product Type

  • Instruments
  • Consumables & Accessories

On the basis of product type, the North America lung cancer diagnostics market is segmented into instruments, consumables & accessories.

Test Type

  • Biomarkers Tests
  • Imaging Test
  • Biopsy
  • Blood Test
  • Others

On the basis of test type, the North America lung cancer diagnostics market is segmented into imaging test, biomarkers test, biopsy, blood test, and others.

Cancer Type

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer

On the basis of cancer type, the North America lung cancer diagnostics market is segmented into non-small cell lung cancer and small cell lung cancer.

End User

  • Hospital
  • Associated Labs
  •  Independent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research Institutes
  • Others

On the basis of end user, the North America lung cancer diagnostics market is segmented into hospital, associated labs, independent diagnostics laboratories, diagnostic imaging centers, cancer research institutes, and others.

Distribution Channel

  • Direct Tender
  • Retail Sales

On the basis of distribution channel, the North America lung cancer diagnostics market is segmented into direct tender and retail sales.

Lung Cancer Diagnostics Market

North America Lung Cancer Diagnostics Market Regional Analysis/Insights

The North America lung cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, end user, and distribution channel, as referenced above.

Some countries covered in the North America lung cancer diagnostics market are the U.S., Canada, and Mexico.

The U.S. is expected to dominate the North America region due to exponential awareness of cancer diagnostics and consultancy services.

The country section of the report also provides individual market-impacting factors and market regulation changes that impact the market's current and future trends. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North American brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and North America Lung Cancer Diagnostics Market Share Analysis

The North America lung cancer diagnostics market competitive landscape provides details by the competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies focus on the North America lung cancer diagnostics market.

Some players in the North America lung cancer diagnostics market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, Vela Diagnostics, DiaSorin S.p.A., Exact Sciences UK, Ltd. (a subsidiary of Exact Science Corporation), 20/20 Gene Systems, Guardant Health, Inc., Inivata Ltd., LalPathLabs.com, LungLife AI, Inc., MedGenome, Myriad Genetics, Inc., NeoGenomics Laboratories, NanoString, Nanoentek, Oncocyte Corporation, PerkinElmer Inc., PlexBio, QIAGEN, Siemens Healthcare GmbH, and Veracyte, Inc. among others.


SKU-

TABLE 1 DIFFERENT TYPES OF CANCER SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS

TABLE 2 LUNG CANCER RATES

TABLE 3 APPROVED DIAGNOSTICS OF LUNGS CANCER

TABLE 4 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 5 NORTH AMERICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 6 NORTH AMERICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 7 NORTH AMERICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 8 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 9 NORTH AMERICA CONSUMABLES & ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 10 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 11 NORTH AMERICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 12 NORTH AMERICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 13 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 14 NORTH AMERICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 15 NORTH AMERICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 16 NORTH AMERICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 17 NORTH AMERICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 18 NORTH AMERICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 NORTH AMERICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 20 NORTH AMERICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 NORTH AMERICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 22 NORTH AMERICA OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 24 NORTH AMERICA NON-SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 NORTH AMERICA SMALL CELL LUNG CANCER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 27 NORTH AMERICA HOSPITAL IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 NORTH AMERICA ASSOCIATED LABS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 29 NORTH AMERICA INDEPENDENT DIAGNOSTIC LABORATORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 NORTH AMERICA DIAGNOSTIC IMAGING CENTERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 NORTH AMERICA CANCER RESEARCH INSTITUTES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 32 NORTH AMERICA OTHERS IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 34 NORTH AMERICA DIRECT TENDER IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 NORTH AMERICA RETAIL SALES IN LUNG CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 36 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)

TABLE 37 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 38 NORTH AMERICA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 39 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 40 NORTH AMERICA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 41 NORTH AMERICA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 42 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 43 NORTH AMERICA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 44 NORTH AMERICA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 45 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 46 NORTH AMERICA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 47 NORTH AMERICA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 48 NORTH AMERICA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 49 NORTH AMERICA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 50 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 51 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 52 NORTH AMERICA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 53 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 54 U.S. INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 55 U.S. PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 56 U.S. IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 57 U.S. BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 58 U.S. CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 59 U.S. KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 60 U.S. REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 61 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 62 U.S. BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 63 U.S. IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 64 U.S. BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 65 U.S. BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 66 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 67 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 68 U.S. LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 69 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 70 CANADA INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 71 CANADA PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 72 CANADA IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 73 CANADA BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 74 CANADA CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 75 CANADA KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 76 CANADA REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 77 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 78 CANADA BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 79 CANADA IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 80 CANADA BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 81 CANADA BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 82 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 83 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 84 CANADA LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 85 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 86 MEXICO INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 87 MEXICO PATHOLOGY-BASED INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 88 MEXICO IMAGING INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 89 MEXICO BIOPSY INSTRUMENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 90 MEXICO CONSUMABLES AND ACCESSORIES IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 91 MEXICO KITS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 92 MEXICO REAGENTS IN LUNG CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)

TABLE 93 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 94 MEXICO BIOMARKERS TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 95 MEXICO IMAGING TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 96 MEXICO BIOPSY IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 97 MEXICO BLOOD TEST IN LUNG CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)

TABLE 98 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)

TABLE 99 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 100 MEXICO LUNG CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The North America Lung Cancer Diagnostics Market is projected to grow at a CAGR of 14.6% during the forecast period by 2030.
The North America Lung Cancer Diagnostics Market is segmented on the basis of product type, test type, cancer type, end user, and distribution channel.
The major players in the North America Lung Cancer Diagnostics Market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott, Quest Diagnostics Incorporated, Biodesix, Amoy Diagnostics Co., Ltd., Bio-Rad Laboratories, Inc., Biocartis, Boditech Med Inc., Danaher, etc.
The countries covered in the North America Lung Cancer Diagnostics Market are U.S., Canada, Mexico.
Free Sample Report

CHOOSE LICENCE TYPE

  • 4200.00
  • 3500.00
  • 2000.00
  • 5500.00
  • 7500.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials